I-125粒子对合并脾功能亢进肝癌患者血常规的影响研究  

Effect of I-125 seeds implantation on routine blood parameters in patients with liver cancer complicated by hypersplenism

作　　者：王凤梅 张文华 陈多兆 白兆娟 西永忠 WANG Fengmei;ZHANG Wenhua;CHEN Duozhao;BAI Zhaojuan;XI Yongzhong(Department of Hepatology,Wuwei Tumor Hospital of Gansu,Wuwei,Gansu,733000,China)

机构地区：[1]甘肃省武威肿瘤医院肝病科,甘肃武威733000 [2]甘肃省武威肿瘤医院超声科,甘肃武威733000

出　　处：《中国冶金工业医学杂志》2025年第2期131-132,共2页Chinese Medical Journal of Metallurgical industry

基　　金：甘肃卫生健康行业科研项目(GSWSQN2021-011);武威市科技局科技计划项目(WW2101113)。

摘　　要：目的 评价放射性碘-125(I-125)粒子植入治疗对合并肝硬化脾功能亢进肝癌患者血常规的影响。方法 选择2019—2022年于我院就诊有肝硬化、脾功能亢进基础的39例原发性肝癌(PLC)患者,均行I-125粒子植入治疗,比较患者治疗前、治疗1周、治疗1个月血常规中白细胞(WBC)、中性粒细胞(NEUT)、红细胞(RBC)、血红蛋白(HGB)、血小板(PLT),血小板宽度(PDW)的水平。结果 合并肝硬化脾功能亢进的肝癌患者行I-125粒子植入治疗前、治疗1周及治疗1个月的WBC、NEUT、RBC、HGB、PLT、PDW水平比较差异均无统计学意义(F=0.641、0.717、0.549、1.354、0.247、0.741,均P>0.05)。结论 I-125粒子对合并肝硬化脾功能亢进肝癌患者的WBC、NEUT、RBC、HGB、PLT、PDW均无明显影响,该类患者也可以安全进行I-125粒子植入治疗。Objective To evaluate the effects of radioactive iodine-125(I-125) seed implantation on routine blood parameters in patients with primary liver cancer(PLC) complicated by cirrhosis and hypersplenism.Methods From 2019 to 2022,39 patients with PLC complicated by cirrhosis and hypersplenism were treated with I-125 seeds implantation in our hospital.Routine blood parameters,including white blood cell(WBC) count,neutrophil(NEUT) count,red blood cell(RBC) count,hemoglobin(HGB),platelet(PLT) count,and platelet distribution width(PDW),were compared before treatment,at 1 week post-treatment,and at 1 month post-treatment.Results There were no statistically significant differences in WBC,NEUT,RBC,HGB,PLT,or PDW levels before treatment,at 1 week,and at 1 month after treatment(F=0.641,0.717,0.549,1.354,0.247,0.741,all P>0.05).Conclusion I-125 seeds implantation does not significantly affect WBC,NEUT,RBC,HGB,PLT,or PDW in PLC patients with cirrhosis and hypersplenism,indicating that the procedure is safe for this patient population.

关 键 词：肝癌 肝硬化 脾功能亢进 I-125粒子植入 血常规 影响 

分 类 号：R817.8[医药卫生—影像医学与核医学]